Marksans Pharma News

This is a corrective phase sparked by fears of a slowdown in earnings. And it is now accompanied by two major headwinds: One, rising oil prices; and two, higher US bond yields. In this scenario, you can well question the logic of looking at mid-caps stocks. So ask yourself this question: Will all the things bothering the market change the business outlook of the company whose stock you want to buy? Consider this: For oil companies that import oil and sell only in the domestic market, the rising rupee is an issue. But for oil companies that import oil, refine it, and then export it, it is much less of an issue. So, while the markets are volatile, try to understand the dynamics of the businesses underlying stocks and decide accordingly.

Kindly find enclosed certificate under reg 74(5) of SEBI (DP) regulations

Kindly find enclosed intimation pursuant to closure of trading window

Kindly find attached

Kindly find enclosed earnings call transcript for Q2FY25 financial performance and strategy update

USFDA approval for Loratadine USP 10mg tablets

Kindly find enclosed

Kindly find enclosed

Kindly find enclosed

Kindly find enclosed

Kindly find enclosed

PFA

PFA

Kind;y find enclosed intimation for Investor(s) / Analyst(s) meet - Q2FY2024-25 earnings conference call

Kindly find enclosed

As enclosed

MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 ,inter alia, to consider and approve the Unaudited Financial Results (Standalone And Consolidated) For The Quarter and half year ended September 30, 2024

Kindly find enclosed

Kindly find enclosed intimation of closure of trading window

Kindly find enclosed the Voting results and scrutinizer report of e-voting held at the 32nd AGM

Kindly find enclosed the proceedings of 32nd AGM of the Company held on September 24, 2024

UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, totaling Rs 480 crore. The largest sale was in Concord Biotech, worth Rs 192 crore at a 15% premium.

NMDC and 38 other companies have set September 17 as the record date to determine shareholders eligible for dividend payments. Today is the last day to buy shares of these companies to qualify for dividends. Investors must purchase shares at least one day before the ex-date to be eligible for dividends.

Kindly find enclosed

Kindly find enclosed newspaper advertisement w.r.t Notice of 32nd Annual General Meeting (''AGM'')

Kindly find enclosed

Kindly find enclosed Business Responsibility and Sustainability Report (BRSR) for FY2023-24

Kindly find enclosed Annual Report for FY2023-24

Kindly find enclosed

Kindly find enclosed newspaper publication given with regards to the 32nd Annual General Meeting of the Company.

Kindly find encloed

Kindly find enclosed

Kindly find enclosed

Kindly find enclosed

Kindly find enclosed

Kindly find enclosed

Kindly find enclosed

Kindly find enclosed

Record date for payment of final dividend

Kindly find enclosed